公开(公告)号：US20190004057A1

公开(公告)日：2019-01-03

申请号：US15737352

申请日：2016-06-17

Applicant: NEUROLOGICAL SURGERY, P.C. ,  RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Seok-Joon Kwon ,  Robert J. Linhardt ,  Jonathan S Dordick ,  William J. Sonstein ,  Fuming Zhang

IPC: G01N33/68 ,  G01N33/543

Abstract: The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

公开(公告)号：US20180050056A1

公开(公告)日：2018-02-22

申请号：US15679709

申请日：2017-08-17

Applicant: KABIO R&D SOO Co., Ltd. ,  Rensselaer Polytechnic Institute

Inventor： Jong Hwan Kwak ,  Kyung Bok Lee ,  Jong-Hwan Park ,  Dong Hee Na ,  Seok-Joon Kwon ,  Robert J. Linhardt ,  Jonathan S. Dordick ,  Fuming Zhang

IPC: A61K31/7016 ,  A61K47/69

CPC classification number: A61K31/7016 ,  A61K47/595 ,  A61K47/6935

Abstract: Provided are a conjugate including a core and sialic acids or derivatives thereof bound to the surface of the core, and use thereof. The conjugate provided in the present invention binds with hemagglutinin on the surface of influenza virus to inhibit the course of infection of influenza virus, thereby preventing or treating infection of influenza virus and also preventing or treating infection of influenza virus resistant to antiviral agents. Accordingly, the conjugate may be widely used in the development of prophylactic or therapeutic agents for influenza virus infection.

公开(公告)号：US20250114394A1

公开(公告)日：2025-04-10

申请号：US18597050

申请日：2024-03-06

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert John LINHARDT ,  So-Young Kim ,  Weihua Jin ,  Jonathan Seth Dordick ,  Fuming Zhang ,  Seok-Joon Kwon ,  Paul S. Kwon ,  Keith Fraser

IPC: A61K31/727 ,  A61K31/737 ,  A61K45/06 ,  A61P31/04

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) via competitive binding to SARS-COV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-COV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-COV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

公开(公告)号：US20250090572A1

公开(公告)日：2025-03-20

申请号：US18899285

申请日：2024-09-27

Applicant: RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert John LINHARDT ,  So-Young Kim ,  Weihua Jin ,  Jonathan Seth Dordick ,  Fuming Zhang ,  Seok-Joon Kwon ,  Paul S. Kwon ,  Keith Fraser

IPC: A61K31/737 ,  A61K31/727 ,  A61P31/14

Abstract: The composition inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via competitive binding to SARS-CoV-2 spike protein. The composition includes a plurality of sulfated glycosaminoglycans which bind to SARS-CoV-2 spike protein, preventing binding to and uptake by host cells. The sulfated glycosaminoglycans, including N-, 2-O, 3-O, or 6-O sulfate groups, or combinations thereof, include heparins and fucoidans, such as those isolated from brown seaweed. The compositions show antiviral activity, with EC50 as low as 0.08 μM, and low cytotoxicity, making it promising for clinical use. While established SARS-CoV-2 treatments such as remdesivir need to be administered intravenously, the compositions discussed herein are advantageously capable to being delivered as a nasal spray, metered dose inhaler, oral delivery, etc.

公开(公告)号：US11067581B2

公开(公告)日：2021-07-20

申请号：US15737352

申请日：2016-06-17

Applicant: NEUROLOGICAL SURGERY, P.C. ,  RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Seok-Joon Kwon ,  Robert J. Linhardt ,  Jonathan S. Dordick ,  William J. Sonstein ,  Fuming Zhang

IPC: G01N33/543 ,  G01N33/68 ,  G01N33/558

Abstract: The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.

公开(公告)号：US10881673B2

公开(公告)日：2021-01-05

申请号：US15679709

申请日：2017-08-17

Applicant: Kabio R&D SOO Co., Ltd. ,  Rensselaer Polytechnic Institute

Inventor： Jong Hwan Kwak ,  Seok-Joon Kwon ,  Robert J. Linhardt ,  Jonathan S. Dordick ,  Fuming Zhang

IPC: A61K31/7016 ,  A61K47/59 ,  A61K47/69

Abstract: Provided are a conjugate including a core and sialic acids or derivatives thereof bound to the surface of the core, and use thereof. The conjugate provided in the present invention binds with hemagglutinin on the surface of influenza virus to inhibit the course of infection of influenza virus, thereby preventing or treating infection of influenza virus and also preventing or treating infection of influenza virus resistant to antiviral agents. Accordingly, the conjugate may be widely used in the development of prophylactic or therapeutic agents for influenza virus infection.

公开(公告)号：US20200345759A1

公开(公告)日：2020-11-05

申请号：US16933043

申请日：2020-07-20

Applicant: Pieter Muntendam ,  RENSSELAER POLYTECHNIC INSTITUTE

Inventor： Robert Linhardt ,  Jing Zhao ,  Fuming Zhang ,  Pieter Muntendam

IPC: A61K31/715 ,  A61K36/42

Abstract: A therapeutic composition includes a polysaccharide, isolated from a member of the genus Cucurbita, e.g., pumpkin, having a backbone including alternating α-L-rhamnosyl (α-L-Rhap) and α-D-galactopyranosyluronic acid (α-D-GapA) residues, and a side chain attached to the backbone including β-D-galactan (β-D-Galp), α-L-arabinofuranosyl (α-L-Araf), or combinations thereof, and a pharmaceutically acceptable excipient. A β-D-Galp side chain is attached to the backbone at the C-4 carbon of at least one α-L-Rhap of the backbone. At least one α-L-Araf is attached to the β-D-Galp side chain. The α-L-Araf is attached to the β-D-Galp side chain via the C-3 carbon of the β-D-Galp. The polysaccharide is effective for treating a galectin-3 dependent disorder by binding to the carbohydrate recognition domain of galectin-3, resulting in inhibition of galectin-3 activity.